| Sign In to gain access to subscriptions and/or personal tools. |
Review: Current status of therapy in autoimmune liver diseaseToronto Western Hospital, Toronto, Canada gideon.hirschfield@ uhn.on.ca
Liver Centre, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Canada
Liver Centre, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Canada Therapeutic strategies for autoimmune liver diseases are increasingly established. Although proportionately uncommon, specialist centers have with time refined the best approaches for each disease, based on an improved understanding of the spectrum of presentation. The major treatment aims are to prevent end-stage liver disease and its associated complications. As a result of drugs such as ursodeoxycholic acid, predniso(lo)ne and azathioprine, both primary biliary cirrhosis and autoimmune hepatitis are now less commonly indications for liver transplantation. Unfortunately, the same inroads in treatment efficacy have as yet not been made for primary sclerosing cholangitis, although the recognition that a subset of patients may have a treatable secondary sclerosing cholangitis (IgG4 related) is helping a proportion. With better biological understanding, more specific interventions are expected that will benefit all those with autoimmune liver diseases.
Key Words: autoimmune hepatitis • primary biliary cirrhosis • primary sclerosing cholangitis • secondary sclerosing cholangitis • autoimmune pancreatitis
Therapeutic Advances in Gastroenterology, Vol. 2, No. 1,
11-28 (2009) |
||||
 |
|
|
 |
Sign In to gain access to subscriptions and/or personal tools.
